Placebo Effect on Mood ImprovementCRC289A07NCT05208294
The Role of Dopamine, Reward Learning and Prefrontal Activity in Expectation-induced Mood Enhancement
A study testing Sulpiride 400 MG, High expectation manipulation and Low expectation manipulation in people with Placebo Effect on Mood Improvement, run by Philipps University Marburg at 1 site in Germany.
Trial summary
Although placebo effects on depressive symptoms are well documented, the underlying mechanisms and moderating factors of expectation effects on mood and depression are poorly understood. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Placebo Effect on Mood Improvement
- What is being tested?
- Sulpiride 400 MG, High expectation manipulation and Low expectation manipulation
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 297 participants
- Where
- 1 siteGermany
- Study dates
- 9 Dec 2021to 22 Sep 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Right-handed
- Aged 18-60 years
- German native speaker
- Informed consent
- Normal or corrected sight
Who cannot join
- Current pregnancy
- Current or history of general medical, neurological or psychological disorders, which preclude sulpiride intake
- Self-reported presence of mental disorders
- Liver, kidney, and bowel disorders
- Regular smoking
- Reported alcohol abuse
Show all 13Show fewer
- Illegal drug intake
- Regular drug intake by prescription in the past three months
- Dreadlocks
- BMI < 19 or > 30
- Unremovable metal objects around the head
- Previous knowledge of Japanese characters
- Excessive caffeine intake (> 8 cups per day)
Trial locations and contacts
1 site in 1 country.
Germany1 site
Department of Psychology, Differential Psychology and Personality Research, Philipps-University of Marburg
Marburg, Hesse, 35032
About this study
Although placebo effects on depressive symptoms are well documented, the underlying mechanisms and moderating factors of expectation effects on mood and depression are poorly understood. Various studies show reduced reward processing in clinical and subclinical depression, presumably due to abnormalities in the dopamine (DA) system. Here, the investigators will test whether expectation-induced mood enhancement is mediated by endogenous DA activity and reward learning, and moderated by individual differences in depression-related personality traits. Healthy participants (N=296) will be tested for potentially relevant personality traits and given an inactive substance (placebo) or a DA D2-receptor antagonist sulpiride (400 mg) in combination with a low vs. high expectation manipulation (fully crossed 2x2 placebo design) before performing a probabilistic reinforcement learning task, an effort expenditure task, and undergo a depressed mood induction procedure. Further, EEG indices will be assessed throughout the tasks.
The investigators expect that positive expectation improves participants' reinforcement learning, increases participants' willingness to make effort in order to obtain reward, and leads to less depressive symptoms as indicated by mood ratings upon depressive mood induction. If the overall effect of positive expectations is mediated by DA, high-dose sulpiride should block expectation-induced effects, i.e., the anticipated enhanced reinforcement learning and effort expenditure as well as mood improvement in the high vs. low expectation group.
Read the detailed description
The placebo effect, i.e., raising expectations towards a successful treatment by applying an inactive substance, reportedly improves therapeutic outcomes in clinical trials. Although there is supporting evidence for the neurotransmitter dopamine (DA) and reinforcement learning, i.e. learning from reward and punishment, to mediate this effect, to the knowledge of the authors, no study has tested these underpinnings yet. The objective of the present project is to investigate whether expectation-induced mood enhancement is mediated by DA activity and reward learning, and moderated by individual differences in depression-related personality traits. To this end, participants will be told to either receive a placebo (low expectation) or a medicine which is labeled as antidepressant (high expectation) that improves mood. Orthogonal to this expectation manipulation, participants actually receive either 400 mg of sulpiride (sulpiride group) or a placebo (inactive substance group). Sulpiride is a selective D2-recptor antagonist which presumably elevates DA levels in low doses and has been used as an antidepressant. However, as a part of the high expectation group's expectation manipulation, while participants are told to receive an antidepressant, the sulpiride group actually receives a dose that is presumably too high to increase DA levels and produce antidepressant effects. Rather, 400mg of sulpirid presumably leads to a blockade of dopamine receptors and may thereby block expectation placebo effects. Participants then undergo three tasks, in which behavioral and computational markers of reinforcement learning and willingness to make effort in order to obtain reward are investigated. Further, mood ratings upon depressive mood induction will be assessed. In addition to participants behavioral responses, EEG indices will be recorded throughout the tasks. Prior to testing, participants will be asked to fill out questionnaires with regard to personality traits as well as reward response. In order to assess dopamine-related plasma prolactin, the study physician will draw one blood sample (ca. 8 ml) at the beginning of the testing session (at approximately 9 a.m.) and one hour after substance intake (at approximately 10 a.m.), which presumably corresponds with the latency of the peak of the prolactin response to sulpiride. Saliva and gene samples will be collected for hypotheses that are tested in the context of the overarching collaborative research center 289 and preregistered elsewhere.
It is expected that positive expectation improves participants' reinforcement learning, increases participants' willingness to make effort in order to obtain reward, and leads to less depressive symptoms as indicated by mood ratings upon depressive mood induction. If the overall effect of positive expectations is mediated by DA, high-dose sulpiride should block expectation-induced effects, i.e., the anticipated enhanced reinforcement learning and effort expenditure as well as mood improvement in the high vs. low expectation group.
Hypotheses:
- Expectation enhancement (high vs. low) within the placebo group is associated with lower negative mood ratings after the mood induction procedure.
- Expectation enhancement (high vs. low) within the placebo group enhances computationally modeled reward learning parameters and EEG markers of reward processing during the reinforcement learning task.
- Within the placebo group, the expectation effect on negative mood ratings mentioned in (1) is correlated with the expectation effect on reward learning parameters in the probabilistic reinforcement learning task mentioned in (2).
- Across the two expectation groups and within the placebo group, reward learning parameters and electrophysiological markers of reward processing are positively correlated with questionnaire measures of agentic extraversion (and negatively with self-reported depressive symptoms).
- In the sulpiride group, the effects described in (1), (2), and (3) are lower than in the placebo group.
- The prolactin response to sulpiride is correlated with the magnitude of expectation effects on reinforcement learning, negative mood, and self-reported agentic extraversion as well as depressive symptoms.
- High levels of the personality trait agentic extraversion (and low levels of depressive symptoms) are associated with higher expectancy effects on negative mood.
- Conditions
- Placebo Effect on Mood Improvement
- Being tested
- Sulpiride 400 MG, Placebo, High expectation manipulation, Low expectation manipulation
- Keywords
- placebo effect, treatment expectations, depression, reinforcement learning, mesolimbic dopamine, EEG
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sulpiride 400 MGDrug
The substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects.
PlaceboDrug
Participants receive an inactive placebo capsule.
High expectation manipulationBehavioural
Participants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated.
Low expectation manipulationBehavioural
Participants will be told by the study clinicians that an inactive placebo capsule is administrated.
| Study group | Role | What they receive |
|---|---|---|
| High expectation with sulpiride group | Experimental | Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a sulpiride 400mg-capsule (note that the dose is presumably too high to produce antidepressant effects). Receives: Drug: Sulpiride 400 MG; Behavioral: High expectation manipulation |
| High expectation with placebo group | Experimental | Prior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a placebo capsule. Receives: Drug: Placebo; Behavioral: High expectation manipulation |
| Low expectation with sulpiride group | Experimental | Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, while participants actually receive a sulpiride capsule (400 mg). Receives: Drug: Sulpiride 400 MG; Behavioral: Low expectation manipulation |
| Low expectation with placebo group | Experimental | Prior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, and participants actually receive a placebo capsule. Receives: Drug: Placebo; Behavioral: Low expectation manipulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Positive and Negative Affect Schedule (PANAS)
With regard to depressive mood induction: the mean of participants' five mood ratings during and immediately after the mood induction procedure. Participants' current mood will be rated on a 5-point Likert scale ranging from 1 = very slightly or not at all to 5 = extremely.
Measured: Five time points: approximately 3 hours after treatment (i.e., substance intake), approximately 4 hours after treatment, approximately 4.5 hours after treatment, approximately 4.75 hours after treatment, and approximately 5 hours after treatment.
The probabilistic reinforcement learning task
With regard to probabilistic reinforcement learning: participants' reward learning rate parameter αG as estimated in computational modeling.
Measured: This will be the first task participants undergo approximately 3 hours after treatment (i.e., substance intake) followed by the two other tasks.
The Effort Expenditure for Rewards Task (EEfRT)
With regard to effort expenditure: The number of participants' choices for the hard task which required more effort.
Measured: This will be the second task participants undergo which follows the probabilistic reinforcement learning task (approximately 4 hours after treatment) followed by the mood induction procedure.
Secondary outcomes (3)
Mood ratings
Several further mood items will be rated on an 8-point scale ranging from 0 = not at all to 8 = very.
Measured: Simultaneously as PANAS (see primary outcome 1).
EEG responses to mood induction
With regard to depressive mood: the late positive potential (LPP) in response to depressive vs. neutral statements, and frontal alpha asymmetry during the 5-minute resting phase immediately after the mood induction procedure.
Measured: Approximately 4. 5 hours after treatment (i.e., during the mood induction procedure which follows the probabilistic reinforcement learning task and the EEfRT tasks).
EEG responses to reward feedback
With regard to probabilistic reinforcement learning: the reward positivity and frontomedial theta power in response to positive vs. negative feedback in the task.
Measured: Approximately 3 hours after treatment (i.e., simultaneously during the probabilistic reinforcement learning task).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jan 2022
- Study start9 Dec 2021
- Primary completion22 Sep 2023
- Study completion22 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Placebo Effect on Mood ImprovementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A fully crossed 2x2 placebo design will be employed by giving participants either a placebo or a sulpiride capsule in combination with a low vs. high expectation manipulation.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 297 participants (actual)
Sponsor and investigators
- Lead sponsor
- Philipps University Marburg
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Erik Müller, Philipps University Marburg
- Investigators
- Erik M Mueller, Prof. Dr., Principal investigator, Philipps University Marburg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05208294
- Sponsor's protocol ID
- CRC 289 Projekt A07
- Acronym
- CRC289A07
- Status last verified
- Jan 2024
- First submitted
- 21 Dec 2021
- Last updated
- 16 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Chuang LC, Augustat N, Bierwirth P, Lees T, Pizzagalli DA, Endres D, Mueller EM. Individual differences in dopamine-related traits influence mood effects of dopamine D2-antagonist and antidepressant treatment expectations. Int J Neuropsychopharmacol. 2025 Nov 3;28(11):pyaf067. doi: 10.1093/ijnp/pyaf067.
PubMed 40966612
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Dopamine, Reward Learning and Prefrontal Activity in Expectation-induced Mood Enhancement
- ClinicalTrials.gov ID
- NCT05208294
- Acronym / sponsor ID
- CRC289A07 / CRC 289 Projekt A07
- Conditions
- Placebo Effect on Mood Improvement
- Keywords
- placebo effect, treatment expectations, depression, reinforcement learning, mesolimbic dopamine, EEG
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 297 participants (actual)
- Lead sponsor
- Philipps University MarburgUniversity, hospital or other
- Study start
- 9 Dec 2021 (actual)
- Primary completion
- 22 Sep 2023 (actual)
- Study completion
- 22 Sep 2023 (actual)
- First posted
- 26 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Although placebo effects on depressive symptoms are well documented, the underlying mechanisms and moderating factors of expectation effects on mood and depression are poorly understood. Various studies show reduced reward processing in clinical and subclinical depression, presumably due to abnormalities in the dopamine (DA) system. Here, the investigators will test whether expectation-induced mood enhancement is mediated by endogenous DA activity and reward learning, and moderated by individual differences in depression-related personality traits. Healthy participants (N=296) will be tested for potentially relevant personality traits and given an inactive substance (placebo) or a DA D2-receptor antagonist sulpiride (400 mg) in combination with a low vs. high expectation manipulation (fully crossed 2x2 placebo design) before performing a probabilistic reinforcement learning task, an effort expenditure task, and undergo a depressed mood induction procedure. Further, EEG indices will be assessed throughout the tasks.
The investigators expect that positive expectation improves participants' reinforcement learning, increases participants' willingness to make effort in order to obtain reward, and leads to less depressive symptoms as indicated by mood ratings upon depressive mood induction. If the overall effect of positive expectations is mediated by DA, high-dose sulpiride should block expectation-induced effects, i.e., the anticipated enhanced reinforcement learning and effort expenditure as well as mood improvement in the high vs. low expectation group.
Detailed description
The placebo effect, i.e., raising expectations towards a successful treatment by applying an inactive substance, reportedly improves therapeutic outcomes in clinical trials. Although there is supporting evidence for the neurotransmitter dopamine (DA) and reinforcement learning, i.e. learning from reward and punishment, to mediate this effect, to the knowledge of the authors, no study has tested these underpinnings yet. The objective of the present project is to investigate whether expectation-induced mood enhancement is mediated by DA activity and reward learning, and moderated by individual differences in depression-related personality traits. To this end, participants will be told to either receive a placebo (low expectation) or a medicine which is labeled as antidepressant (high expectation) that improves mood. Orthogonal to this expectation manipulation, participants actually receive either 400 mg of sulpiride (sulpiride group) or a placebo (inactive substance group). Sulpiride is a selective D2-recptor antagonist which presumably elevates DA levels in low doses and has been used as an antidepressant. However, as a part of the high expectation group's expectation manipulation, while participants are told to receive an antidepressant, the sulpiride group actually receives a dose that is presumably too high to increase DA levels and produce antidepressant effects. Rather, 400mg of sulpirid presumably leads to a blockade of dopamine receptors and may thereby block expectation placebo effects. Participants then undergo three tasks, in which behavioral and computational markers of reinforcement learning and willingness to make effort in order to obtain reward are investigated. Further, mood ratings upon depressive mood induction will be assessed. In addition to participants behavioral responses, EEG indices will be recorded throughout the tasks. Prior to testing, participants will be asked to fill out questionnaires with regard to personality traits as well as reward response. In order to assess dopamine-related plasma prolactin, the study physician will draw one blood sample (ca. 8 ml) at the beginning of the testing session (at approximately 9 a.m.) and one hour after substance intake (at approximately 10 a.m.), which presumably corresponds with the latency of the peak of the prolactin response to sulpiride. Saliva and gene samples will be collected for hypotheses that are tested in the context of the overarching collaborative research center 289 and preregistered elsewhere.
It is expected that positive expectation improves participants' reinforcement learning, increases participants' willingness to make effort in order to obtain reward, and leads to less depressive symptoms as indicated by mood ratings upon depressive mood induction. If the overall effect of positive expectations is mediated by DA, high-dose sulpiride should block expectation-induced effects, i.e., the anticipated enhanced reinforcement learning and effort expenditure as well as mood improvement in the high vs. low expectation group.
Hypotheses:
- Expectation enhancement (high vs. low) within the placebo group is associated with lower negative mood ratings after the mood induction procedure.
- Expectation enhancement (high vs. low) within the placebo group enhances computationally modeled reward learning parameters and EEG markers of reward processing during the reinforcement learning task.
- Within the placebo group, the expectation effect on negative mood ratings mentioned in (1) is correlated with the expectation effect on reward learning parameters in the probabilistic reinforcement learning task mentioned in (2).
- Across the two expectation groups and within the placebo group, reward learning parameters and electrophysiological markers of reward processing are positively correlated with questionnaire measures of agentic extraversion (and negatively with self-reported depressive symptoms).
- In the sulpiride group, the effects described in (1), (2), and (3) are lower than in the placebo group.
- The prolactin response to sulpiride is correlated with the magnitude of expectation effects on reinforcement learning, negative mood, and self-reported agentic extraversion as well as depressive symptoms.
- High levels of the personality trait agentic extraversion (and low levels of depressive symptoms) are associated with higher expectancy effects on negative mood.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- A fully crossed 2x2 placebo design will be employed by giving participants either a placebo or a sulpiride capsule in combination with a low vs. high expectation manipulation.
| Arm | Type | Receives |
|---|---|---|
| High expectation with sulpiride group | Experimental | Drug: Sulpiride 400 MG, Behavioral: High expectation manipulationPrior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a sulpiride 400mg-capsule (note that the dose is presumably too high to produce antidepressant effects). |
| High expectation with placebo group | Experimental | Drug: Placebo, Behavioral: High expectation manipulationPrior to the experimental procedure, participants are told by the study clinicians that an antidepressant sulpiride capsule is administrated, while participants actually receive a placebo capsule. |
| Low expectation with sulpiride group | Experimental | Drug: Sulpiride 400 MG, Behavioral: Low expectation manipulationPrior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, while participants actually receive a sulpiride capsule (400 mg). |
| Low expectation with placebo group | Experimental | Drug: Placebo, Behavioral: Low expectation manipulationPrior to the experimental procedure, participants are told by the study clinicians that an inactive placebo capsule is administrated, and participants actually receive a placebo capsule. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Right-handed
- Aged 18-60 years
- German native speaker
- Informed consent
- Normal or corrected sight
Key exclusion criteria (13 listed)
- Current pregnancy
- Current or history of general medical, neurological or psychological disorders, which preclude sulpiride intake
- Self-reported presence of mental disorders
- Liver, kidney, and bowel disorders
- Regular smoking
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sulpiride 400 MGThe substituted benzamide sulpiride is a selective D2-receptor antagonist that is generally well tolerated and has a low affinity to histaminergic, cholinergic, serotonergic, adrenergic, or GABA receptors. Sulpiride is slowly absorbed from the gastrointestinal tract and peak serum levels occur at 3 hours . In low doses (50-200 mg), sulpiride presumably blocks presynaptic autoreceptors, thereby elevating DA levels and reducing depressive symptoms, whereas higher doses lead to a predominant blockade of postsynaptic receptors. The dose in the present study (400 mg) is sufficient for behaviorally relevant modulations of dopaminergic processing with minimal risk of side effects. Note that participants in the sulpiride group actually receive a dose that is presumably too high to produce antidepressant effects. | Drug | High expectation with sulpiride group, Low expectation with sulpiride group |
| PlaceboParticipants receive an inactive placebo capsule. | Drug | High expectation with placebo group, Low expectation with placebo group |
| High expectation manipulationParticipants will be told by the study clinicians that an antidepressive sulpiride capsule is administrated. | Behavioural | High expectation with placebo group, High expectation with sulpiride group |
| Low expectation manipulationParticipants will be told by the study clinicians that an inactive placebo capsule is administrated. | Behavioural | Low expectation with placebo group, Low expectation with sulpiride group |
Primary outcome
The Positive and Negative Affect Schedule (PANAS)
Time frame: Five time points: approximately 3 hours after treatment (i.e., substance intake), approximately 4 hours after treatment, approximately 4.5 hours after treatment, approximately 4.75 hours after treatment, and approximately 5 hours after treatment.
With regard to depressive mood induction: the mean of participants' five mood ratings during and immediately after the mood induction procedure. Participants' current mood will be rated on a 5-point Likert scale ranging from 1 = very slightly or not at all to 5 = extremely.
The probabilistic reinforcement learning task
Time frame: This will be the first task participants undergo approximately 3 hours after treatment (i.e., substance intake) followed by the two other tasks.
With regard to probabilistic reinforcement learning: participants' reward learning rate parameter αG as estimated in computational modeling.
The Effort Expenditure for Rewards Task (EEfRT)
Time frame: This will be the second task participants undergo which follows the probabilistic reinforcement learning task (approximately 4 hours after treatment) followed by the mood induction procedure.
With regard to effort expenditure: The number of participants' choices for the hard task which required more effort.
3 secondary outcomes
Mood ratings
Time frame: Simultaneously as PANAS (see primary outcome 1).
EEG responses to mood induction
Time frame: Approximately 4. 5 hours after treatment (i.e., during the mood induction procedure which follows the probabilistic reinforcement learning task and the EEfRT tasks).
EEG responses to reward feedback
Time frame: Approximately 3 hours after treatment (i.e., simultaneously during the probabilistic reinforcement learning task).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2024.
- Derived from this study: PubMed 40966612Chuang LC, Augustat N, Bierwirth P, Lees T, Pizzagalli DA, Endres D, Mueller EM. Individual differences in dopamine-related traits influence mood effects of dopamine D2-antagonist and antidepressant treatment expectations. Int J Neuropsychopharmacol. 2025 Nov 3;28(11):pyaf067. doi: 10.1093/ijnp/pyaf067.
- Individual participant dataSharing planned: Yes
Related trials for Placebo Effect on Mood Improvement
Not yet recruiting
Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood and Anxiety
General Anxiety Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Erik M Mueller, Prof. Dr. principal investigator
Philipps University Marburg
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sulpiride 400 MG, High expectation manipulation and Low expectation manipulation in people with Placebo Effect on Mood Improvement, run by Philipps University Marburg at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Positive and Negative Affect Schedule (PANAS) (time frame: Five time points: approximately 3 hours after treatment (i.e., substance intake), approximately 4 hours after treatment, approximately 4.5 hours after treatment, approximately 4.75 hours after treatment, and approximately 5 hours after treatment.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05208294, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2024.